Europe - FRA:0QF - US60770K1079 - Common Stock
Taking everything into account, 0QF scores 3 out of 10 in our fundamental rating. 0QF was compared to 76 industry peers in the Biotechnology industry. While 0QF seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, 0QF is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -24.17% | ||
ROE | -30.89% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 68.32% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 3.16 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.93 | ||
Quick Ratio | 3.77 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
FRA:0QF (9/19/2025, 7:00:00 PM)
21.4
-0.54 (-2.44%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.17 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.04 | ||
P/tB | 1.05 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -24.17% | ||
ROE | -30.89% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 68.32% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 386.06% | ||
Cap/Sales | 26.09% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.93 | ||
Quick Ratio | 3.77 | ||
Altman-Z | 3.16 |